<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01728064</url>
  </required_header>
  <id_info>
    <org_study_id>EPI2010-006</org_study_id>
    <nct_id>NCT01728064</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia</brief_title>
  <official_title>Safety and Efficacy Study of EPI-743 on Visual Function in Patients With Friedreich's Ataxia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Edison Pharmaceuticals Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Edison Pharmaceuticals Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine the effects of EPI-743 on visual function and
      neurologic function in patients with Friedreich's ataxia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Function</measure>
    <description>Low contrast visual acuity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Color vision</measure>
    <description>Roth 28 hue test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurologic function</measure>
    <description>Friedreich's ataxia rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuromuscular function</measure>
    <description>25-foot walk test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuromuscular function</measure>
    <description>9-hole peg test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <description>SF-36</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease biomarkers</measure>
    <description>Blood biomarker levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <description>Echocardiogram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <description>Number of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease improvement</measure>
    <description>Patient Global Improvement Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Function</measure>
    <time_frame>Baseline, Months 3, 6, 9 and 12</time_frame>
    <description>Visual field exam</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Friedreich's Ataxia</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI-743 400 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPI-743 at a dose of 400 mg three times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EPI-743 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EPI-743 at a dose of 200 mg three times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743 400 mg</intervention_name>
    <arm_group_label>EPI-743 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EPI-743 200 mg</intervention_name>
    <arm_group_label>EPI-743 200 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Diagnosis of genetically confirmed Friedreich's ataxia

          2. Visual acuity at baseline more than 15 letters on EDTRS at four meters

          3. FARS score of 20 to 90

          4. Agreement to use contraception if within reproductive years (see specifics in section
             D1, page 21)

          5. Hormone replacement therapy, if used, must remain stable for the duration of the study

          6. Willingness and ability to comply with study procedures

          7. Willingness and ability to arrive at study site day prior to evaluations

          8. Abstention from use of dietary supplements and non-prescribed medications at least 30
             days prior to initiation of treatment and for the duration of the study. This would
             specifically include idebenone, Coenzyme Q10 and vitamin E

          9. Abstention from use of other investigative or non-approved drugs within 30 days of
             enrollment and for the duration of the study

        Exclusion Criteria:

          1. Allergy to EPI-743 or sesame oil or nuts

          2. Clinically significant bleeding condition or abnormal PT/PTT INR (INR &gt; two; PTT &gt;
             two-times normal)

          3. Liver insufficiency with LFTs greater than three-times upper normal limit at screening

          4. Renal insufficiency with creatinine &gt; 1.5 at screening

          5. Fat malabsorption syndromes

          6. Any other respiratory chain diseases of the mitochondria or inborn errors of
             metabolism

          7. Any other ophthalmologic conditions

          8. History of alcohol or drug abuse

          9. Clinically significant cardiomyopathy with ejection fraction &lt; 40 percent at screening

         10. Clinically significant arrhythmia within past two years requiring treatment

         11. Anticoagulant therapy within 30 days of enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2012</study_first_submitted>
  <study_first_submitted_qc>November 13, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2012</study_first_posted>
  <last_update_submitted>March 18, 2016</last_update_submitted>
  <last_update_submitted_qc>March 18, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Friedreich's</keyword>
  <keyword>Ataxia</keyword>
  <keyword>FRDA</keyword>
  <keyword>FA</keyword>
  <keyword>EPI-743</keyword>
  <keyword>Edison</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ataxia</mesh_term>
    <mesh_term>Cerebellar Ataxia</mesh_term>
    <mesh_term>Friedreich Ataxia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

